<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858050</url>
  </required_header>
  <id_info>
    <org_study_id>13/16</org_study_id>
    <nct_id>NCT02858050</nct_id>
  </id_info>
  <brief_title>Portal-724 MEMS for Medication Adherence Patients Taking HCV Medications</brief_title>
  <official_title>A Randomized, Parallel-group, Pilot Study on the Effect of Using the Portal724-Medication Electronic Medication System (MEMS) Smart Cap With Real-time Medication Adherence Among Patients Being Treated With Grazoprevir/Elbasvir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Michael's Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Saint Michael's Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will look at real-time adherence monitoring with Portal-724 MEMS cap. It integrates
      medication bottle, Smart Cap, Pill Dispenser, Embedded Computer, Embedded Cellular Modem and
      Tamper Proof apparatus. This device is capable of transmitting pill dispensing events from
      the patient's home to the Cloud over Cellular and IP networks. The transmission is done in
      real time if cellular coverage is above 1-bar, but if the cell signal is not available or if
      the signal is below the threshold, then the device Store-and-Forward feature is automatically
      activated. The patient will be randomized to real-time monitoring or to have monitoring data
      download monthly at each study visit while taking hepatitis C medications
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C virus (HCV) infection is a very important health problem worldwide. Majority of
      the estimated 160 million people infected globally are unaware of their affliction [1]. It is
      a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. In the
      United States alone, HCV infection is the most common chronic blood-borne infection,
      affecting about 3.2 million individuals The study will look at real-time adherence monitoring
      with Portal-724 MEMS cap. It integrates medication bottle, Smart Cap, Pill Dispenser,
      Embedded Computer, Embedded Cellular Modem and Tamper Proof apparatus. This device is capable
      of transmitting pill dispensing events from the patient's home to the Cloud over Cellular and
      IP networks. The transmission is done in real time if cellular coverage is above 1-bar, but
      if the cell signal is not available or if the signal is below the threshold, then the device
      Store-and-Forward feature is automatically activated. The patient will be randomized to
      real-time monitoring or to have monitoring data download monthly at each study visit while
      taking hepatitis C medications
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2016</start_date>
  <completion_date type="Actual">January 25, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Use of Portal724-MEMS Service on Medication Adherence in the Treatment of Hepatitis C in Patients, Defined as Compliance to Regimen 95% of the Time.</measure>
    <time_frame>1 year</time_frame>
    <description>Number of Participants with Compliance to Regimen 95% of the Time Due to Portal724-MEMS Service</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Adherence</condition>
  <arm_group>
    <arm_group_label>MEMs Cap Real-Time Monitoring</arm_group_label>
    <description>Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEMs Cap Without Real-Time Monitoring</arm_group_label>
    <description>Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Portal-724 MEMs Cap</intervention_name>
    <arm_group_label>MEMs Cap Real-Time Monitoring</arm_group_label>
    <arm_group_label>MEMs Cap Without Real-Time Monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Treatment-naïve and treatment-experienced genotype 1 or 4 HCV patients with or without
        compensated cirrhosis will be enrolled in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 18 years old and above.

          2. HCV treatment naïve or HCV trreatment experienced

          3. HCV RNA PCR &gt; 10,000 IU/L

          4. Confirmed infection with Hepatitis C virus (HCV) by HCV serum antibody assay and by
             HCV Ribonucleic Acid (RNA) Polymerase Chain Reaction (PCR) and Confirmed chronicity
             with 2 PCR's 6 months apart.

          5. Patients with HCV Genotype 1, 4

          6. Patients are candidates for treatment of HCV with oral Direct-Acting Agents (DAA)

          7. understand the study procedures, alternative treatments available, risks involved with
             the study, and voluntarily agrees to participate by giving written informed consent

        Exclusion Criteria:

          1. Patient not willing to sign written informed consent

          2. Patients deemed not suitable for HCV treatment as deemed by the treating physician at
             the liver center

          3. Patients with decompensated liver cirrhosis, defined as follows:

               1. Liver biopsy within the last year showing Scheuer Stage 4 or transient
                  elastography (Fibroscan®) in the last year with a reading of &gt;12.5 kPa; AND

               2. Any clinical sign of hepatic decompensation such as ascites (fluid in the
                  abdomen), jaundice (yellowing of eyes and skin), esophageal varices with bleeding
                  (enlarged veins of the esophagus seen on endoscopy) or hepatic encephalopathy
                  (tremors, confusion, sleepiness)

          4. Co-Infection with the Hepatitis B virus

          5. Any liver disease of non-HCV etiology such as Hemochromatosis, Wilson's Disease,
             Alcoholic liver disease or Non-Alcoholic Steato-Hepatitis (NASH)

          6. Hepatocellular carcinoma or any other malignancy

          7. Untreated psychiatric conditions such as major depression, schizophrenia, bipolar
             disorder which in the opinion of the Principal Investigator will not interfere with
             protocol visit and/or procedures

          8. Current and untreated substance abuse (cocaine, opiates, alcohol, marijuana, other
             recreational drugs, controlled substances)

          9. Patient is pregnant or breastfeeding.

         10. Patients unwilling to use cellular phones

         11. Patients unwilling to follow specific instructions for medication intake

         12. Patient has any of the following conditions:

               -  Organ transplants (including hematopoietic stem cell transplants) other than
                  cornea and hair.

               -  Poor venous access that precludes routine peripheral blood sampling required for
                  this trial.

               -  History of gastric surgery (e.g., stapling, bypass) or subject with a history of
                  malabsorption disorders (e.g., celiac sprue disease).

               -  History of a medical/surgical condition that resulted in hospitalization within
                  the 3 months prior to enrollment, other than for minor elective procedures

               -  Medical/surgical conditions that may result in a need for hospitalization during
                  the period of the study

               -  any medical condition requiring, or likely to require, chronic systemic
                  administration of corticosteroids, TNF antagonists, or other immunosuppressant
                  drugs during the course of the trial

         13. has exclusionary laboratory values as listed below: Noncirrhotic/Cirrhotic Subjects
             Creatinine clearance &lt; 50 mL/min Hemoglobin &lt;9.5 g/dL for both male and female
             subjects Platelets &lt;50 x 103/μL serum albumin &lt; 3.0 g/dL INR &gt;1.7, unless subject has
             a stable INR on an anticoagulant regimen. HbA1c &gt;10% ALT &gt;10XULN AST &gt;10XULN

         14. is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or
             child) who is investigational site or sponsor staff directly involved with this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihad Slim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Micahel's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <results_first_submitted>April 25, 2018</results_first_submitted>
  <results_first_submitted_qc>December 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2018</results_first_posted>
  <last_update_submitted>December 10, 2018</last_update_submitted>
  <last_update_submitted_qc>December 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Michael's Medical Center</investigator_affiliation>
    <investigator_full_name>Jihad Slim, MD</investigator_full_name>
    <investigator_title>Chief and Program Director, Infectious Diseases</investigator_title>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02858050/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Portal-724 MEMs Cap Real-Time Monitoring</title>
          <description>Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time
Portal-724 MEMs Cap</description>
        </group>
        <group group_id="P2">
          <title>Portal-724 MEMs Cap Without Real-Time Monitoring</title>
          <description>Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications
Portal-724 MEMs Cap</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Portal-724 MEMs Cap Real-Time Monitoring</title>
          <description>Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time
Portal-724 MEMs Cap</description>
        </group>
        <group group_id="B2">
          <title>Portal-724 MEMs Cap Without Real-Time Monitoring</title>
          <description>Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications
Portal-724 MEMs Cap</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Caucasion</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment Naive</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Use of Portal724-MEMS Service on Medication Adherence in the Treatment of Hepatitis C in Patients, Defined as Compliance to Regimen 95% of the Time.</title>
        <description>Number of Participants with Compliance to Regimen 95% of the Time Due to Portal724-MEMS Service</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Portal-724 MEMs Cap Real-Time Monitoring</title>
            <description>Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time
Portal-724 MEMs Cap</description>
          </group>
          <group group_id="O2">
            <title>Portal-724 MEMs Cap Without Real-Time Monitoring</title>
            <description>Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications
Portal-724 MEMs Cap</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Portal724-MEMS Service on Medication Adherence in the Treatment of Hepatitis C in Patients, Defined as Compliance to Regimen 95% of the Time.</title>
          <description>Number of Participants with Compliance to Regimen 95% of the Time Due to Portal724-MEMS Service</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.548306</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Portal-724 MEMs Cap Real-Time Monitoring</title>
          <description>Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time
Portal-724 MEMs Cap</description>
        </group>
        <group group_id="E2">
          <title>Portal-724 MEMs Cap Without Real-Time Monitoring</title>
          <description>Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications
Portal-724 MEMs Cap</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation to our pilot study might be the small sample size and a larger study might detect a difference in adherence.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jihad Slim, MD</name_or_title>
      <organization>Saint Michael's Medical Center</organization>
      <phone>9738772663</phone>
      <email>jsmdsmmc@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

